Evidence map›Paper›PMID 42581399›Full record

ArticleProtein science : a publication of the Protein Society2026

A cryptic allosteric pocket shapes isoform-selective inhibition of human malic enzymes.

Ben A Krinkel, Yuliana Yosaatmadja, Mark D Slayton, Anita Krinkel, Jack Copping, Jin Heon Jeon, Joyce Eu, Kerslee Kohagen, Amir Ashoorzadeh, Jeff Smaill and 5 more

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A cryptic allosteric pocket shapes isoform-selective inhibition of human malic enzymes.Protein science : a publication of the Protein Society · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ben A KrinkelSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.ORCID 0000-0003-3980-0438
Yuliana YosaatmadjaSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.ORCID 0000-0003-2875-5993
Mark D SlaytonDepartment of Internal Medicine, University of Michigan, Michigan Medicine, Ann Arbor, Michigan, USA.ORCID 0000-0002-7321-032X
Anita KrinkelSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.ORCID 0009-0000-6949-4035
Jack CoppingDepartment of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand.
Jin Heon JeonDepartment of Internal Medicine, University of Michigan, Michigan Medicine, Ann Arbor, Michigan, USA.ORCID 0000-0002-8427-8514
Joyce EuDepartment of Internal Medicine, University of Michigan, Michigan Medicine, Ann Arbor, Michigan, USA.ORCID 0009-0002-0448-8560
Kerslee KohagenDepartment of Internal Medicine, University of Michigan, Michigan Medicine, Ann Arbor, Michigan, USA.ORCID 0009-0008-1739-8488
Amir AshoorzadehMaurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.ORCID 0000-0001-8462-7879
Jeff SmaillMaurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.ORCID 0000-0003-2954-6093
Jack FlanaganMaurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand.ORCID 0000-0002-3246-2248
Christopher WalkerSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.ORCID 0000-0001-8151-4123
Sofia D MerajverDepartment of Internal Medicine, University of Michigan, Michigan Medicine, Ann Arbor, Michigan, USA.ORCID 0000-0002-6823-7130
Kerry LoomesSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.ORCID 0000-0002-7562-3216
Christopher J SquireSchool of Biological Sciences, The University of Auckland, Auckland, New Zealand.ORCID 0000-0001-9212-0461

Funding

Maurice and Phyllis Paykel TrustMaurice Wilkins CentreSchool of Biological Sciences Research Development FundScience Faculty Research Development FundUniversity of Auckland
6 · The paper itself

Abstract

Malic enzymes (ME) regulate central carbon metabolism and cellular redox balance, and the mitochondrial isoform ME2 is frequently upregulated in aggressive cancers to support metabolic flexibility and stress resistance. Isoform-selective inhibition has remained out of reach because the catalytic machinery is essentially invariant across the three human enzymes (ME1-3), suggesting that selectivity must arise elsewhere than the active site. Here, we define matched kinetic and regulatory profiles for all three isoforms, highlighting key differences in substrate and cofactor dependence and metabolic regulation. Our x-ray crystal structures show that the active-site inhibitor 3',6'-dihydroxy-4,4″-dimethoxy-[1,1':4',1″-terphenyl]-2',5'-dione (NPD-389) occupies a conserved, metal-coordinating pose in all three isoforms, explaining its non-selective inhibition observed in enzyme assays. We further identify a cryptic pocket adjacent to the active site that is engaged by our probe molecule, flavianic acid (FLA), and accessible only in the mitochondrial enzymes ME2 and ME3. FLA binding locks an open, inactive enzyme conformation in place, with kinetic studies revealing isoform-specific allosteric responses and suggesting that this pocket may be a native regulatory site sensitive to the mitochondrial metabolic state. Our cellular viability assays suggest that molecules exploiting this cryptic pocket reduce proliferation in cancer cell models with elevated ME2 expression. Conformational dynamics, rather than sequence divergence at the catalytic center, can therefore generate isoform-specific regulatory and inhibitory mechanisms within a conserved enzyme family.

Indexed as

Enzyme InhibitorsMalate DehydrogenaseAllosteric RegulationAllosteric SiteCatalytic DomainCrystallography, X-RayHumansIsoenzymesKineticsModels, MolecularEnzyme InhibitorsIsoenzymesMalate Dehydrogenasemalate dehydrogenase (decarboxylating)allosteric regulationcancerflavianic acidhuman malic enzyme (ME1, ME2, ME3)metabolismNPD‐389structure‐based drug designx‐ray crystallography

Identifiers

PMID42581399
PMCPMC13461788

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.